1. Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)–Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women
- Author
-
Jemima Nyakio, Catia T. Perciani, Timothy Kotikot, Borna A. Nyaoke, Nelly Wanjiku, Kelly S. MacDonald, Rose Ndambuki, Marion Agwaya, Sabrina Hundal, Lyle R. McKinnon, Rose Mahira, Elizabeth Mutiska, Matrona Akiso, Emmanuel Museve, Catherine Kamau, Lewa Said, Julius Oyugi, H Ogutu, Hannah Nduta Gakure, A. Omu Anzala, James Wakonyo, Robert Langat, Judith Omungo, Jacquelyn Nyange, Mercy Musanga, Walter Jaoko, Mario A. Ostrowski, Lydia Atambo, Roselyne Malogo, Ruth Chirchir, Simon Ogola, Jason Ndalamia, Jackton Indangasi, Laura Lusik, Moses Muriuki, Bashir Farah, Catherine Ngeli, Naomi Mwakisha, Joshua Kimano, Manmeet Sekhon, Erastus Irungu, Brian Onsembe, Richard Alila, Irene Mwangi, Mary W Gichuho, Dorothy Essendi, and Gaudensia Mutua
- Subjects
0301 basic medicine ,Immunoglobulin A ,Herpesvirus 3, Human ,HIV/AIDS vaccine ,vaccine vector ,zoster vaccine ,viruses ,virus ,Antibodies, Viral ,Vaccines, Attenuated ,medicine.disease_cause ,Virus ,Major Articles and Brief Reports ,03 medical and health sciences ,Immunity ,Herpes Zoster Vaccine ,Humans ,Immunology and Allergy ,Medicine ,Mucous Membrane ,Reactogenicity ,integumentary system ,biology ,business.industry ,Immunogenicity ,Varicella zoster virus ,virus diseases ,biochemical phenomena, metabolism, and nutrition ,Kenya ,eye diseases ,Immunity, Humoral ,3. Good health ,Vaccination ,030104 developmental biology ,Infectious Diseases ,Varicella Zoster Virus Infection ,varicella zoster ,Vagina ,Viruses ,Immunology ,biology.protein ,mucosal immunity ,Female ,Zoster vaccine ,business ,medicine.drug - Abstract
We show that VZV-seropositive women sustain VZV-specific humoral immunity at the gastrointestinal and genital mucosa and that this immunity can be boosted upon vaccination. Our findings encourage further investigation of VZV as a potential vector in vaccines including HIV., Background Attenuated varicella zoster virus (VZV) is a promising vector for recombinant vaccines. Because human immunodeficiencyvirus (HIV) vaccines are believed to require mucosal immunogenicity, we characterized mucosal VZV-specific humoral immunity following VZVOka vaccination. Methods Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine. The anamnestic responses to the virus were followed longitudinally in both plasma and mucosal secretions using an in-house glycoprotein enzyme-linked immunosorbent assay and safety and reactogenicity monitored. VZV seroprevalence and baseline responses to the virus were also characterized in our cohorts (n = 288). Results Besides boosting anti-VZV antibody responses systemically, vaccination also boosted anti-VZV immunity in the cervicovaginal mucosa with a 2.9-fold rise in immunoglobulin G (P < .0001) and 1.6-fold rise in immunoglobulin A (IgA) (P = .004) from the time before immunization and 4 weeks postvaccination. Baseline analysis demonstrated high avidity antibodies at the gastrointestinal and genital mucosa of VZV-seropositive women. Measurement of VZV-specific IgA in saliva is a sensitive tool for detecting prior VZV infection. Conclusions VZVOka vaccine was safe and immunogenic in VZV-seropositive adult Kenyan women. We provided compelling evidence of VZV ability to induce genital mucosa immunity. Clinical Trials Registration NCT02514018.
- Published
- 2018